Andy coleads our Strategy & Corporate Finance Practice globally, helping leaders and organizations accelerate sustainable and inclusive growth through strategy development, innovation, portfolio management, effective capital-markets engagement and communications, IPOs, M&A, and divestitures. He works across sectors, including life sciences, healthcare, high tech, and industrials, and collaborates with companies to realize a step-change in performance. He focuses on helping organizations create and deliver strategy, ensure effective CEO and CFO transitions, drive large-scale portfolio change and transformation, and deliver the full potential of all facets of M&A.
His experience also spans restructuring and cost management, investor relations, and large-scale reorganization. He has worked extensively in the Americas, Asia, and Europe. Andy’s recent client work includes the following:
- leading a portfolio transformation for a specialty pharmaceutical company, involving reallocating more than $40 billion in capital to high-growth market segments, a dozen transactions, and building deep M&A capabilities, leading to a five-fold increase in market capitalization
- helping a materials-science organization redeploy $20 billion in capital, including programmatic M&A and investor relations strategy to identify, evaluate, and engage target companies over an 18-month period
- delivering a multiyear strategy and performance transformation for a private company, creating a two-fold increase in valuation and ultimately resulting in an IPO
- developing a growth strategy to significantly expand cross-selling and new market opportunities for a medical-equipment provider in the context of a major portfolio shift, including M&A, divestiture, and organic acceleration
